NCT03341520View on ClinicalTrials.gov

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

November 11, 2021

Study Completion Date

May 31, 2024

Conditions
Stage II Grade 1 Follicular LymphomaStage II Grade 2 Follicular LymphomaStage I Follicular Lymphoma Grade 1Stage II Follicular Lymphoma Grade 2
Interventions
DRUG

Obinutuzumab Injection [Gazyva]

7x 1000mg flat dose

RADIATION

Low dose radiation Therapy (LDRT)

2 x 2 Gy

Trial Locations (12)

45122

University of Essen, Essen

50924

University of Cologne, Cologne

60590

University of Frankfurt, Frankfurt

69120

University of Heidelberg, Heidelberg

81377

LMU, Munich

81675

TU, Munich

89081

University of Ulm, Ulm

Unknown

University of Tuebingen, Tübingen

Vivantes Klinikum, Berlin

Klinikum Kempten, Kempten

Site Marburg, Marburg

University of Muenster, Münster

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Heidelberg University

OTHER

NCT03341520 - Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma | Biotech Hunter | Biotech Hunter